A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease

Recruiting

InnAVasc GraftA Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease

Sponsor:

W.L.Gore & Associates

Code:

NCT04671771

Conditions

End Stage Renal Disease (ESRD)

Kidney Failure

Chronic Renal Disease

Hemodialysis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

InnAVasc Arteriovenous Graft (IG) surgical implant

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-13. This information was provided to ClinicalTrials.gov by W.L.Gore & Associates on 2025-12-22.